Expression data from CD138+ cells obtained from MM patients at diagnosis

ABSTRACT: Thalidomide-dexamethasone (TD) combination is an effective induction therapy for newly diagnosed multiple myeloma patients, candidates for subsequent autologous stem cell transplantation (ASCT). Since maximization of tumor response before ASCT may favorably affect the clinical outcomes, we designed a study to identify a gene expression profile (GEP) signature predictive of attainment of complete response to TD induction therapy. CD138+ bone marrow samples obtained at diagnosis from 112/311 patients were analyzed. Two subsequent time phases were planned. Firstly, a GEP supervised analysis, performed on a training set of 32 patients, allowed to identify 157 probe sets differentially expressed in complete responder + near complete responder (CR+nCR) versus ?partial responder patients. Than, w

ORGANISM(S): Homo sapiens

SUBMITTER: Carolina Terragna 

PROVIDER: E-GEOD-16791 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress